Finanzen von Aldeyra Therapeutics Inc (ALDX)ALDXAldeyra Therapeutics Inc

Evaluating the bottom line, Aldeyra Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -49.48%, provide a clear picture of how effectively ALDX converts its operational activities into shareholder value.

In the context of the broader market, ALDX competes directly with industry leaders such as RLYB and ICCC. With a market capitalization of $94.11M, it holds a leading position in the sector. When comparing efficiency, ALDX's gross margin of N/A stands against RLYB's 100.00% and ICCC's 33.92%. Such benchmarking helps identify whether Aldeyra Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Aldeyra has consistently reported negative net income, with Q2 2026 showing a loss of -$5,450,273. The company has a forward P/E ratio of 0, indicating no expected earnings growth in the near future, and a debt-to-equity ratio of 0%, which suggests it has no current debt obligations but also raises concerns about its financial health.